HSA
NMRA icon

HBK Sorce Advisory’s Neumora Therapeutics NMRA Stock Holding History

HBK Sorce Advisory’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Sell
16,232
-805
-5% -$1.53K ﹤0.01% 660
2026
Q1 		$31.2K Hold
17,037
– – ﹤0.01% 646
2025
Q4 		$36.1K Buy
17,037
+194
+1% +$425 ﹤0.01% 618
2025
Q3 		$31K Buy
16,843
+611
+4% +$988 ﹤0.01% 611
2025
Q2 		$11.9K Buy
+16,232
New +$12.3K ﹤0.01% 593

Other funds holding NMRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AH
Addis & Hill Wayne, Pennsylvania $181M AUM 21.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

HBK Sorce Advisory's NMRA Position: Q2 2026 in Review

HBK Sorce Advisory reduced its Neumora Therapeutics (NMRA) stake by 4.7% in Q2 2026, selling an estimated $1.53K and leaving 16,232 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #660.

HBK Sorce Advisory first reported a position in NMRA in Q2 2025 and has held it in 5 quarters since. The position peaked at $36.1K in Q4 2025. 35 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • HBK Sorce Advisory held 16,232 shares of Neumora Therapeutics worth $26.1K as of Q2 2026.
  • HBK Sorce Advisory sold 805 Neumora Therapeutics shares in Q2 2026, an estimated $1.53K.
  • Neumora Therapeutics made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #660 holding.
  • HBK Sorce Advisory first reported a position in Neumora Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • HBK Sorce Advisory's Neumora Therapeutics position peaked at $36.1K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.